Related references
Note: Only part of the references are listed.Intraperitoneal treatment of malignant ascites due to epithelial tumors with catumaxomab: A phase II/III study
S. Parsons et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Characterisation of the new EpCAM-specific antibody HO-3:: implications for trifunctional antibody immunotherapy of cancer
P. Ruf et al.
BRITISH JOURNAL OF CANCER (2007)
Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody:: A phase I/II study
Alexander Burges et al.
CLINICAL CANCER RESEARCH (2007)
Immunotherapy of malignant ascites with trifunctional antibodies
MM Heiss et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Malignant ascites: Past, present, and future
RA Adam et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2004)
Malignant ascites - New concepts in pathophysiology, diagnosis, and management
N Aslam et al.
ARCHIVES OF INTERNAL MEDICINE (2001)
Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody
P Ruf et al.
BLOOD (2001)
Share Paper
